Absence of inhibitory effect of levocetirizine on the metabolism of human cytochrome P450 model substrates Source: Eur Respir J 2005; 26: Suppl. 49, 136s Year: 2005
The perpetrator potential of sitaxentan based on its ability to inhibit human cytochrome P450 (CYP) enzymes Source: Annual Congress 2008 - Pulmonary vascular disease and other pulmonary conditions: miscellaneous Year: 2008
Cytochrome P450 pharmacogenetics: a possible predictor of pulmonary drug induced toxicity? Source: Eur Respir J 2007; 30: Suppl. 51, 488s Year: 2007
Expression of xenobiotic-metabolizing enzymes in human pulmonary tissue: possible role in susceptibility for ILD Source: Eur Respir J 2001; 18: 122S-126S Year: 2001
Effects of aryl hydrocarbon receptor and cytochrome P450 1A1 polymorphisms on childhood lung function and asthma Source: Eur Respir J 2007; 30: Suppl. 51, 296s Year: 2007
Association analysis between polymorphisms in the cytochrome P450 2J2, 2S1 and UDP-glucuronosyltransferase 2B7 genes with occupational chronic bronchitis Source: Annual Congress 2010 - Genetics of obstruction Year: 2010
The victim potential of sitaxentan: metabolism by human CYP450 enzymes Source: Annual Congress 2008 - Pulmonary vascular disease and other pulmonary conditions: miscellaneous Year: 2008
The perpetrator potential of sitaxentan: human CYP enzyme induction Source: Annual Congress 2008 - Pulmonary vascular disease and other pulmonary conditions: miscellaneous Year: 2008
Cytochrome P450 1A1 polymorphism and severity of COPD Source: Eur Respir J 2002; 20: Suppl. 38, 212s Year: 2002
Safety and pharmacology of a soluble epoxide hydrolase inhibitor Source: International Congress 2015 – New targets and modalities for the treatment of asthma and COPD Year: 2015
Epoxyeicosatrienoates are the dominant eicosanoids in human lungs upon microbial challenge Source: Eur Respir J 2010; 36: 1088-1098 Year: 2010
‘Total PDE4 inhibitory activity‘: a concept for evaluating pharmacokinetic alterations of roflumilast and roflumilast N-oxide in special populations and drug-drug interactions Source: Eur Respir J 2006; 28: Suppl. 50, 436s Year: 2006
Comparison of inhibitory potentials of pranlukast and zafirlukast on human liver CYP isoforms Source: Eur Respir J 2003; 22: Suppl. 45, 102s Year: 2003
Effect of CYP3A4 inhibitors verapamil and itraconazole on the pharmacokinetics of AZD7986, an oral DPP1 inhibitor Source: International Congress 2017 – Asthma management Year: 2017
Genetic polymorphisms in the cytochromes P450, microsomal epoxide hydrolase and glutathione S-transferase M1, T1 and P1 genes and their relationship to relapsing bronchitis and pneumonia in case of children Source: Eur Respir J 2005; 26: Suppl. 49, 167s Year: 2005
Cytochrome P450 2A5 methylation and gene expression profile is organ-specific and affected by maternal smoking during pregnancy Source: International Congress 2018 – Functional genomics and COPD: new challenges Year: 2018
In vitro pharmacological characterization of CHF6001, a novel selective phosphodiesterase 4 (PDE4) inhibitor with a robust anti-inflammatory profile Source: International Congress 2014 – Novel targets and drugs for asthma and COPD Year: 2014
Cytochrome CYP2C9 and vitamin K epoxide reductase gene polymorphisms in patients with pulmonary embolism treated with warfarin Source: Annual Congress 2007 - The role of gene polymorphisms in pulmonary disease susceptibility Year: 2007
Role of cytochromes - general aspects Source: Lung Science Conference 2006 - Hypoxia in Lung Biology and Disease Year: 2006
Effect of the CYP3A4 inhibitor ketoconazole on the pharmacokinetics and pharmacodynamics of AZD5069, an oral CXCR2 antagonist Source: International Congress 2014 – Novel evidence relating to respiratory treatment development Year: 2014